StockData
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. (CRDF) stock

CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.85−0.04 (-4.46%)

Close on Nov 20, 2026Market cap $66.34MP/E –Yield –

Cardiff Oncology r&d expenses

Research and development expenses are spending on new products and technology.

Cardiff Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $25.95M, down 37.3% year over year. For fiscal 2025 it was $35.33M, down 4.1% from the year before. Over ten years it grew 12.8% a year on average. The highest annual figure on record is $36.85M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$35.33M-4.1%
FY2024Dec 31, 2024$36.85M+12.2%
FY2023Dec 31, 2023$32.86M+21.2%
FY2022Dec 31, 2022$27.11M+56.0%
FY2021Dec 31, 2021$17.38M+54.7%
FY2020Dec 31, 2020$11.24M+0.7%
FY2019Dec 31, 2019$11.16M+36.7%
FY2018Dec 31, 2018$8.16M+3.6%
FY2017Dec 31, 2017$7.88M-47.5%
FY2016Dec 31, 2016$15.01M+41.7%
FY2015Dec 31, 2015$10.59M+59.0%
FY2014Dec 31, 2014$6.66M+68.8%
FY2013Dec 31, 2013$3.95M+105.6%
FY2012Dec 31, 2012$1.92M+110.9%
FY2011Dec 31, 2011$910.69K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.92M-48.9%
Q1 FY2026Mar 31, 2026$6.77M-35.4%
Q4 FY2025Dec 31, 2025$5.08M-47.7%
Q3 FY2025Sep 30, 2025$8.20M-15.0%
Q2 FY2025Jun 30, 2025$11.58M+22.0%
Q1 FY2025Mar 31, 2025$10.48M+30.8%
Q4 FY2024Dec 31, 2024$9.71M+25.1%
Q3 FY2024Sep 30, 2024$9.64M+20.2%
Q2 FY2024Jun 30, 2024$9.49M+18.4%
Q1 FY2024Mar 31, 2024$8.01M-11.5%
Q4 FY2023Dec 31, 2023$7.76M+20.5%
Q3 FY2023Sep 30, 2023$8.02M+33.5%
Q2 FY2023Jun 30, 2023$8.02M+7.7%
Q1 FY2023Mar 31, 2023$9.05M+25.6%
Q4 FY2022Dec 31, 2022$6.44M+10.6%
Q3 FY2022Sep 30, 2022$6.01M+44.7%
Q2 FY2022Jun 30, 2022$7.45M+80.8%
Q1 FY2022Mar 31, 2022$7.21M+119.8%
Q4 FY2021Dec 31, 2021$5.82M+82.1%
Q3 FY2021Sep 30, 2021$4.15M+45.5%
Q2 FY2021Jun 30, 2021$4.12M+66.4%
Q1 FY2021Mar 31, 2021$3.28M+21.2%
Q4 FY2020Dec 31, 2020$3.20M+11.7%
Q3 FY2020Sep 30, 2020$2.86M+1.3%
Q2 FY2020Jun 30, 2020$2.48M-12.5%
Q1 FY2020Mar 31, 2020$2.71M+2.2%
Q4 FY2019Dec 31, 2019$2.86M+14.7%
Q3 FY2019Sep 30, 2019$2.82M+54.0%
Q2 FY2019Jun 30, 2019$2.83M+44.9%
Q1 FY2019Mar 31, 2019$2.65M+40.6%
Q4 FY2018Dec 31, 2018$2.50M+107.0%
Q3 FY2018Sep 30, 2018$1.83M+29.4%
Q2 FY2018Jun 30, 2018$1.95M+98.9%
Q1 FY2018Mar 31, 2018$1.88M-56.0%
Q4 FY2017Dec 31, 2017$1.21M-68.1%
Q3 FY2017Sep 30, 2017$1.41M-64.1%
Q2 FY2017Jun 30, 2017$981.72K–
Q1 FY2017Mar 31, 2017$4.28M–
Q4 FY2016Dec 31, 2016$3.78M–
Q3 FY2016Sep 30, 2016$3.94M–

More Cardiff Oncology figures

See a number that looks wrong?